July 26, 1999
AMERIPATH ACQUIRES PENNSYLVANIA PATHOLOGY PRACTICE

Riviera Beach, FL, July 26, 1999 -- AmeriPath, Inc. (Nasdaq: PATH), a physician group practice and laboratory management company focused on anatomic pathology services, announced today that it has completed the acquisition of Consulting Pathologists, P.A., an outpatient pathology practice with locations in the Philadelphia, Pennsylvania area. The practice had annualized net revenues of $4.4 million. Terms of the transactions were not disclosed.

Consulting Pathologists is AmeriPath's second acquisition in the state of Pennsylvania and its first in the Philadelphia area. The practice employs five physicians and 62 technical and administrative personnel. The practice has established relationships with SmithKline Beecham Clinical Laboratories (NYSE:SBH) and with Quest Diagnostics, Inc. (NYSE:DGX).

"The addition of Consulting Pathologists, with Dr. Gordon Fink as Managing Director, will enhance our position and regional business model in the state of Pennsylvania," said James C. New, Chairman and CEO of AmeriPath. "This is of strategic significance to our growth strategies with the national clinical laboratories and our entry into the northeast U.S. market."

AmeriPath, Inc. is the nation's leading physician group practice and laboratory management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories, and managed care organizations. The Company presently operates in twelve states and employs 256 pathologists who provide medical services through outpatient pathology laboratories, hospital inpatient laboratories, and outpatient surgery centers.

..........................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursement, changes on reimbursement coding guidelines, dependence upon contracts and pathologists, acquisitions and affiliations, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.